Roche’s Genentech is paying $30 million (€28 million) upfront to work with UK Biotech Bicycle Therapeutics on the development of immuno-oncology therapies. Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones as the assets progress. Source: Fierce Biotech 25/1/2020